" /> " />

Zomedica Pharmaceuticals Earnings Estimate

ZOM Stock  USD 0.13  0.0002  0.15%   
By analyzing Zomedica Pharmaceuticals' earnings estimates, investors can diagnose different trends across Zomedica Pharmaceuticals' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Zomedica Pharmaceuticals Corp is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
Zomedica Pharmaceuticals is projected to generate -0.0025 in earnings per share on the 31st of December 2024. Zomedica Pharmaceuticals earnings estimates module stress-tests analyst consensus about projected Zomedica Pharmaceuticals Corp EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Many public companies, such as Zomedica Pharmaceuticals, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Zomedica Pharmaceuticals' earnings estimates, investors can diagnose different trends across Zomedica Pharmaceuticals' analyst sentiment over time as well as compare current estimates against different timeframes. At this time, Zomedica Pharmaceuticals' Gross Profit is very stable compared to the past year. As of the 24th of April 2024, Gross Profit Margin is likely to grow to 0.79, while Pretax Profit Margin is likely to drop (1.49).
  
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons.

Zomedica Pharmaceuticals Earnings per Share Projection vs Actual

About Zomedica Pharmaceuticals Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Zomedica Pharmaceuticals earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Zomedica Pharmaceuticals estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Zomedica Pharmaceuticals fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-170.9 M-162.4 M
Retained Earnings Total Equity-122.8 M-116.6 M
Earnings Yield(0.18)(0.18)
Price Earnings Ratio(5.68)(5.97)
Price Earnings To Growth Ratio(0.06)(0.05)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Zomedica Pharmaceuticals is a strong investment it is important to analyze Zomedica Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zomedica Pharmaceuticals' future performance. For an informed investment choice regarding Zomedica Stock, refer to the following important reports:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Complementary Tools for Zomedica Stock analysis

When running Zomedica Pharmaceuticals' price analysis, check to measure Zomedica Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zomedica Pharmaceuticals is operating at the current time. Most of Zomedica Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Zomedica Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zomedica Pharmaceuticals' price. Additionally, you may evaluate how the addition of Zomedica Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Is Zomedica Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.04)
Revenue Per Share
0.026
Quarterly Revenue Growth
0.192
Return On Assets
(0.07)
Return On Equity
(0.14)
The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zomedica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.